 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H14N2 |
| Molar mass | 162.236 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Rivanicline (TC-2403,RJR-2403,(E)-metanicotine) is a drug which acts as apartial agonist at neuralnicotinic acetylcholine receptors. It is subtype-selective, binding primarily to theα4β2subtype. It hasnootropic effects and was originally developed as a potential treatment forAlzheimer's disease,[1][2][3] but a second action that was subsequently found was that it inhibits the production ofInterleukin-8 and thus produces anantiinflammatory effect, and so it has also been developed as a potential treatment forulcerative colitis.[4] Rivanicline also hasstimulant andanalgesic actions which are thought to be mediated through stimulation ofnoradrenaline release,[5] and so it could also have other applications. It has been identified as constituent of tobacco as well.[6][7]
{{cite journal}}:Cite journal requires|journal= (help)